$An exceptional response to olaparib in relapsed and refractory BRCA2 mutated non-small cell lung cancer in hereditary breast–ovarian cancer syndrome$

An exceptional response to olaparib in relapsed and refractory BRCA2 mutated non-small cell lung cancer in hereditary breast–ovarian cancer syndrome

Bibliographic Details
Main Authors:	Vikas T. Talreja, Vanita Noronha, Amit Joshi, Vijay Patil, Kumar Prabhash
Format:	Article
Language:	English
Published:	Thieme Medical and Scientific Publishers Pvt. Ltd. 2020-01-01
Series:	South Asian Journal of Cancer
Online Access:	http://www.thieme-connect.de/DOI/DOI?10.4103/sajc.sajc_157_19

Similar Items

An exceptional response to nivolumab in relapsed and refractory malignant mesothelioma
by: Vikas T Talreja, et al.
Published: (2019-01-01)

Desperate times, desperate measures: Low-dose nivolumab-induced remission in relapsed NSCLC
by: Vikas T Talreja, et al.
Published: (2019-01-01)

Synchronous primary of periampullary and lung cancer: A case report and review of literature
by: Vikas Talreja, et al.
Published: (2018-01-01)

Lorlatinib in anaplastic lymphoma kinase-positive non-small cell lung cancer: Indian experience
by: Vikas T. Talreja, et al.
Published: (2020-01-01)

Coexistence of epidermal growth factor receptor mutation and anaplastic lymphoma kinase translocation in non-small cell lung cancer: Do we know the treatment sequence?
by: Vikas T Talreja, et al.
Published: (2019-01-01)

Survey for geriatric assessment in practicing oncologists in India
by: Vanita Noronha, et al.
Published: (2019-01-01)

Real-World Experience of Patients with Inoperable, Stage III Non-small-Cell Lung Cancer Treated with Durvalumab after Chemoradiotherapy: Indian Experience
by: Vanita Noronha, et al.
Published: (2020-07-01)

Olaparib maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer
by: S V Khokhlova
Published: (2017-09-01)

Olaparib as maintenance treatment for patients with platinum-sensitive relapsed ovarian cancer
by: Jonathan A. Ledermann, et al.
Published: (2019-05-01)

Systemic treatment options in bladder cancer
by: Rahul Ravind, et al.
Published: (2018-01-01)

Third-line therapy in the epidermal growth factor receptor mutation-positive advanced nonsmall-cell lung cancer
by: Vanita Noronha, et al.
Published: (2020-01-01)

OCTOVA: A randomised phase II trial of olaparib, chemotherapy, or olaparib and cediranib in patients with BRCA-mutated platinumresistant ovarian cancer
by: Nicum, S, et al.
Published: (2017)

Spotlight on olaparib in the treatment of BRCA-mutated ovarian cancer: design, development and place in therapy
by: Lorusso D, et al.
Published: (2018-05-01)

Evolving role of immunotherapy in head-and-neck cancers: A systemic review
by: Raajit Chanana, et al.
Published: (2018-01-01)

Role of palliative chemotherapy and targeted therapy in advanced esophageal and gastroesophageal junction cancers
by: Vijai Simha, et al.
Published: (2019-01-01)

Cost-effectiveness analysis of olaparib as maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer and a BRCA1/2 mutation in china
by: Yamin Shu, et al.
Published: (2022-08-01)

Olaparib in the management of ovarian cancer
by: Bixel K, et al.
Published: (2015-08-01)

Authors' reply to Kulkarni et al. and Wiwanitkit
by: Amit Kumar Agrawal, et al.
Published: (2020-01-01)

Concomitant use of corticosteroids and immune checkpoint inhibitors in patients with solid neoplasms: A real-world experience from a tertiary cancer center
by: Akhil Kapoor, et al.
Published: (2019-01-01)

Chemoprevention in head and neck cancer
by: Joydeep Ghosh, et al.
Published: (2016-01-01)

Cytomegalovirus infection in solid malignancies
by: Amit Kumar Agrawal, et al.
Published: (2020-01-01)

Cost-effectiveness analysis of olaparib maintenance therapy for BRCA mutation ovarian cancer in the public sector in Malaysia.
by: Chee Meng Yong, et al.
Published: (2024-01-01)

Cancer thrombosis: Narrative review
by: Pritesh Naresh Munot, et al.
Published: (2020-01-01)

Oral metronomic therapy in head and neck cancer – Authors' reply
by: Vijay Patil, et al.
Published: (2021-01-01)

Genomic Profile and BRCA-1 Promoter Methylation Status in BRCA Mutated Ovarian Cancer: New Insights in Predictive Biomarkers of Olaparib Response
by: Elisena Franzese, et al.
Published: (2019-11-01)

Bendamustine in the third line or beyond in metastatic, recurrent, or relapsed head-and-neck cancers: A retrospective observational study
by: Vijay Patil, et al.
Published: (2022-01-01)

BRCA1 and BRCA2 rearrangements in Brazilian individuals with Hereditary Breast and Ovarian Cancer Syndrome
by: Ingrid Petroni Ewald, et al.
Published: (2016-06-01)

BRCA1 and BRCA2 rearrangements in Brazilian individuals with Hereditary Breast and Ovarian Cancer Syndrome
by: Ingrid Petroni Ewald, et al.
Published: (2016-06-01)

Cabazitaxel for Metastatic Castration-Resistant Prostate Cancer: Retrospective Data Analysis from an Indian Centre
by: Vanita Noronha, et al.
Published: (2016-08-01)

Evaluating homologous recombination activity in tissues to predict the risk of hereditary breast and ovarian cancer and olaparib sensitivity
by: Tokiwa Motonari, et al.
Published: (2024-04-01)

Experience in the use of olaparib poly (ADP-ribose) polymerase inhibitors in maintenance therapy of BRCA-associated ovarian cancer
by: V. N. Zhurman, et al.
Published: (2023-02-01)

BRCA2 reversion mutation confers resistance to olaparib in breast cancer
by: Shinya Yamamoto, et al.
Published: (2023-06-01)

The role of BRCA1/2 in hereditary and familial breast and ovarian cancers
by: Yousef M. Hawsawi, et al.
Published: (2019-09-01)

Molecular biology of head and neck cancers
by: Deepa Philip, et al.
Published: (2016-01-01)

Practical aspects of treating relapsed BRCA-associated ovarian cancer
by: A. A. Rumyantse, et al.
Published: (2019-12-01)

Profile of olaparib in the treatment of advanced ovarian cancer
by: Chase DM, et al.
Published: (2016-04-01)

Authors' response to Vora and Rajpurohit
by: Vanita Noronha, et al.
Published: (2020-01-01)

Clinical Benefits of Olaparib in Mexican Ovarian Cancer Patients With Founder Mutation BRCA1-Del ex9-12
by: Dolores Gallardo-Rincón, et al.
Published: (2022-06-01)

Combination of triapine, olaparib, and cediranib suppresses progression of BRCA-wild type and PARP inhibitor-resistant epithelial ovarian cancer.
by: Z Ping Lin, et al.
Published: (2018-01-01)

Epidermal growth factor receptor-mutated non-small-cell lung cancer: A primer on contemporary management
by: Akhil Rajendra, et al.
Published: (2019-01-01)